top of page

NET RETREAT: Retreatment with 177Lu-DOTATATE vs Everolimus in Metastatic Midgut NET

NET RETREAT: Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors


DRUG/TREATMENT: Lu-177 Dotatate PRRT or Everolimus


STATUS: Not Yet Recruiting

SPONSOR: National Cancer Institute (NCI)

Dr. Aman Chauhan Discusses NET Retreat


This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to treatment with everolimus in patients with midgut neuroendocrine tumors that have spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). 

PRRT involves treatment with a radioactive substance that is linked to a peptide receptor so that it will attach to a specific cell type when injected into the body. 177Lu-DOTATATE, a PRRT drug, may increase the length of time until worsening of disease by 8 months compared to the usual approach. 

Everolimus treats cancer by stopping cancer cells from reproducing and by decreasing blood supply to the cancer cells. Everolimus prevents transplant rejection by decreasing the activity of the immune system. Giving 177Lu-DOTATATE may work better in shrinking and stabilizing tumors in patients with neuroendocrine tumors.

For more information on eligibility criteria, trial locations, study details, etc., go to to view this trial here.

CONTACT/Principal Investigators:

Dr. Simron Singh, Canadian Cancer Trials Group

Dr. Aman Chauhan, SWOG Cancer Research Network

bottom of page